Newsroom News Archive Publications Contact Us for Experts
Media Contacts
Kate Olderman
(215) 349-8369

Related Links
Perelman School of Medicine
University of Pennsylvania Health System

Recommend Story
 
> Epigenetics Shapes Fate of Brain vs. Brawn Castes in Carpenter Ants
> Molecular Master Switch for Pancreatic Cancer Identified, Potential Predictor of Treatment Outcome
> Eat to Dream: Penn Study Shows Dietary Nutrients Associated with Certain Sleep Patterns
  All News Releases
 
    Media Resources
 
spacerNEWS RELEASE spacer Print Version
APRIL 16 , 2007
 

Penn Researchers Find Treatment for MS also Reduces Vision Loss in MS Patients

  First MS Study to Include a Test of Visual Function
   
> Researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI®) – a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS) – also reduces vision loss in patients with relapsing MS. 
> Researchers found vision loss – a worsening of vision defined as a two-line (10-letter) reduction in letter chart scores – was reduced by as much as 47% among people taking natalizumab, compared to those taking placebo. 
> The study appears in the April 17 issue of Neurology.

(PHILADELPHIA) – According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI®) – a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS) – also reduces vision loss in patients with relapsing MS.  Vision loss is one of the most common and disabling symptoms of MS.

“Not only does natalizumab prevent the worsening of vision loss in people with relapsing MS, but it is also associated with significant reductions in the likelihood of sustained vision loss due to inflammatory demyelination of nerve fibers that connect to the eye, a common cause of visual loss in MS,” says Laura J. Balcer, MD, MSCE, Associate Professor of Neurology and Ophthalmology at Penn, and lead author of the paper. 

Low-Contrast Letter Chart

Using low-contrast letter acuity charts, researchers found vision loss - a worsening of vision defined as a two-line (10-letter) reduction in letter chart scores - was reduced by as much as 47% among people with MS taking natalizumab, compared to those taking placebo.

Image Courtesy: Precision Vision, LaSalle IL

The researchers analyzed data from two randomized, double-blind, placebo-controlled, parallel group, phase 3 clinical trials involving 2,138 men and women with relapsing MS from clinical centers in Europe, North America, Australia, and New Zealand.  More than half of the participants received natalizumab every four weeks for two years, while the remaining participants received placebo.  Visits were conducted every 12 weeks and visual function testing was performed at each study visit.  Low-contrast letter acuity was measured using low-contrast letter charts (eye charts with gray letters on a white background).

Researchers found vision loss – a worsening of vision defined as a two-line (10-letter) reduction in letter chart scores – was reduced by as much as 47% among people taking natalizumab, compared to those taking placebo. 

"Not only do the findings of the study add to our understanding of the effects of natalizumab, but the results provide strong validation for a simple, sensitive, cost-effective, and clinically meaningful measure of visual function in MS," advises Dr. Nicholas LaRocca, Associate Vice President, Health Care Delivery and Policy Research at the National MS Society.

The researchers caution that, as with any therapy, the benefits of natalizumab must be considered in the context of potential risks or complications.  In the case of natalizumab, three confirmed cases of progressive multifocal leukoencephalopathy (PML) – a rare, often lethal brain disease – have been reported.

Despite the fact that vision loss is a common and important cause of disability in MS, the natalizumab clinical trials were the first to include a test of visual function.  These trials showed that low-contrast letter acuity eye chart testing is an effective measure for assessing visual outcomes, and may be useful in future clinical trials.

This study was supported by Biogen Idec and Elan, makers of natalizumab.  Dr. Balcer has received support for consulting from Biogen Idec as well as from other companies for work on developing visual outcome measures for MS clinical trials.

###

PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

 



About Penn Medicine   Contact Us   Site Map   Privacy Statement   Legal Disclaimer   Terms of Use

Penn Medicine, Philadelphia, PA 800-789-PENN © 2013, The Trustees of the University of Pennsylvania